Revvity shares are higher after its Q1 2026 results beat expectations on adjusted EPS, helping offset mixed reactions to a lower full-year profit outlook. The company also highlighted portfolio actions, including plans to divest its China Immunodiagnostics business.
1. What’s driving RVTY higher today
Revvity (RVTY) is moving up after reporting first-quarter 2026 results that came in ahead of Wall Street expectations on profitability, with adjusted EPS of $1.06 and revenue of about $711 million. The print is being treated as a sign the company’s margin and mix initiatives are holding up even as parts of the end-market remain uneven. (ir.revvity.com)
2. The key numbers investors are reacting to
The headline catalyst is the earnings beat: adjusted EPS of $1.06 topped consensus estimates (around $1.02–$1.04), while revenue grew year over year. Investors are focusing on the bottom-line delivery and operational execution, which can matter more than small top-line variability in a quarter where cost control and mix improvement are in focus. (investing.com)
3. The main pushback: guidance cut
One reason the move isn’t larger is that Revvity reduced its 2026 adjusted profit guidance range to roughly $5.20–$5.30 per share (from about $5.35–$5.45 previously). Even so, the stock is higher as investors appear to be prioritizing the near-term beat and confidence in the longer-term margin trajectory over the lowered full-year EPS framework. (investing.com)
4. Strategic backdrop: portfolio moves and capital return
Beyond the quarter, Revvity also flagged portfolio actions, including plans tied to its China immunodiagnostics business, which investors may view as a way to sharpen the company’s mix and reduce complexity. The company also continued share repurchases in the quarter, adding support to per-share results and the broader “execution + capital return” narrative around the name. (stocktitan.net)
RVTY•
